05:57 PM EDT, 10/16/2025 (MT Newswires) -- Kezar Life Sciences ( KZR ) plans to explore strategic alternatives following regulatory delays on its autoimmune hepatitis drug candidate, while a restructuring to reduce costs is expected to include job cuts.

The company said Thursday it has been "unable to align" with the US Food and Drug Administration on a potential registrational clinical trial of its experimental drug zetomipzomib, and that the agency canceled a Type C meeting scheduled to discuss a proposed study in autoimmune hepatitis.

The company had cash, cash equivalents and marketable securities of $90.2 million as of Sept. 30.

Additionally, Kezar adopted an amendment to extend its rights plan.

Kezar shares jumped 45% in after-hours trading.